New combination therapy for type 2 diabetes
Part of Hormones & metabolism clinical trials.
This study tests a new combination of medicines (AD-233A, AD-233B, AD-233C, and/or AD-233D) to see if they help control blood sugar and are safe. It may be an option for people with type 2 diabetes who do not have severe complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be willing to give written consent to join the study.
- You cannot have severe complications from diabetes, like serious kidney problems, severe eye damage, or major nerve issues.
- There may be other health requirements that the study team will check with you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, HD-6277, to see if it can help lower blood sugar in adults with type 2 diabetes that isn't well managed by diet and exercise alone.
This trial tests a new drug called AD-123 and compares it to taking two other drugs (AD-1231 and AD-1232) together. It is for healthy adults to see how the body handles the drugs and if they are safe.
This study tests a new combination of three diabetes medicines for people recently diagnosed with type 2 diabetes. It aims to see if this triple therapy controls blood sugar better than the standard two-drug approach.
This study combines two different diabetes medications (called DWP16001 and DWC202518) to see if starting them together works better than either one alone for lowering blood sugar. It is for adults with type 2 diabetes who need better control and have not yet tried or have only taken one diabetes pill.
This trial tests a new combination pill that includes three medications to lower blood sugar in people with type 2 diabetes. It aims to see if this combination is safe and effective for Chinese patients.
This trial tests a combination of three diabetes medicines (henagliflozin proline, retagliptin, and metformin) for people newly diagnosed with type 2 diabetes. The goal is to see how well the combination controls blood sugar and to check its safety.
Hear when a new Type 2 Diabetes Mellitus (T2DM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.